Carbon Monoxide Inhibition of Mitochondrial Function and Efficacy of a Novel Antidotal Therapeutic for Carbon Monoxide Poisoning
一氧化碳对线粒体功能的抑制以及新型一氧化碳中毒解毒疗法的功效
基本信息
- 批准号:9121057
- 负责人:
- 金额:$ 7.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffinityAnimal Disease ModelsAnimal ModelAnisotropyAntidotesAwardBindingBiochemistryBiological AssayBiological MarkersBiologyBloodBlood PressureBlood VesselsBradycardiaBreathingBusinessesCarbon MonoxideCarbon Monoxide PoisoningCarboxyhemoglobinCardiacCardiovascular systemCarrying CapacitiesCathetersCessation of lifeChemistryClinicClinicalComorbidityComplexCritical CareCytochromesDataDevelopmentEffectivenessElectrodesElectron TransportEnzymesErythrocytesFunctional Magnetic Resonance ImagingFunctional disorderGlobinGlucoseHeartHeart MitochondriaHeart RateHemoglobinHumanHyperbaric OxygenHypotensionIn VitroIndividualInjuryLaboratoriesLactic AcidosisLevel of EvidenceLungMeasuresMentorsMitochondriaModelingMolecularMusMyocardialMyocardial dysfunctionNational Research Service AwardsNeurocognitive DeficitNeurologicNeurologic DeficitOrganOutcomeOxidasesOxygenPathologicPatientsPharmaceutical PreparationsPharmacology and ToxicologyPoisoningRecombinantsReperfusion InjuryResearchResearch InfrastructureResourcesRespirationRodentRodent ModelSafetySchoolsStagingStatistical ModelsSuggestionTestingTherapeuticTherapeutic AgentsTissuesToxic effectTrainingTranslational ResearchTroponinUnited StatesUnited States National Institutes of HealthUniversitiesawakebench to bedsidecomplex IVcytochrome c oxidasedrug developmentexperienceheme ahemodynamicshigh riskhypoperfusionimprovedin vivomitochondrial dysfunctionmortalitymouse modelmutantneuroglobinnovelnovel therapeuticspre-clinicalprogramspublic health relevanceresearch and developmentresponsescale upskillstissue respirationtool
项目摘要
DESCRIPTION (provided by applicant): Carbon monoxide (CO) exposure is the leading cause of human poisoning in the United States, with 50,000 cases every year. Current therapy, normobaric or hyperbaric oxygen, has limited effectiveness and is difficult to deliver. There is currently no antidotal therapy. Our understanding of the toxic effects of CO is two-fold: CO directly binds to hemoglobin reducing oxygen carrying capacity of the blood, and CO directly binds to a heme in cytochrome c oxidase, inhibiting mitochondrial respiration. The major sequelae of CO poisoning - cardiovascular dysfunction and acute and long term neurologic deficits - are dependent on impaired mitochondrial function. Our lab has developed an agent, recombinant human neuroglobin (rNgb), with a very high affinity for CO, which has the potential to reduce the toxic effects of CO poisoning. We, therefore, propose the hypothesis that treatment with rNgb reverses the toxic effects of CO poisoning on mitochondrial function. To test the hypothesis, we will first conduct in vitro studies using a Clark-like electrode to further characterize the toxic effects of CO on isolated mitochondria and heart tissue respiration and demonstrate that rNgb can reverse the toxic effects of CO on mitochondrial respiration. Second, in an in vivo CO poisoning model, we will show that treatment with rNgb can reverse pathologic changes as assessed by functional MRI changes (fractional anisotropy) and blood levels of lactate and glucose. These results will provide pre-clinical proof of concept for rNgb to act as a potential therapeutic agent in CO poisoning. In parallel, through the NIH SMARTT program we are conducting pharmacology and toxicology testing and scaling up drug manufacturing capabilities. The NRSA award will allow me, a pulmonary and critical care trained fellow, a unique opportunity to leverage the existing research and development infrastructure of my mentor, Dr. Mark Gladwin, to gain advanced training in animal models of disease, mitochondrial biology, and pathophysiologic outcomes. In addition, I am pursuing an MBA in the entrepreneurial track at the Tepper School of Business at Carnegie Mellon University, which will provide extensive training in finance, statistical modeling, and critical tools for bringing a potential therapeutic drug from bench to bedside. The resources and experience of my mentor Dr Gladwin, an expert in NO and globin biochemistry, as well as the translational development of drugs from the laboratory to the clinic, and my co- mentor Dr Shiva, an expert in mitochondrial biology, combined with the expansive array of resources available at the University of Pittsburgh, will allow me develop new translational research skills with a specific focus on development of novel therapeutic strategies.
描述(申请人提供):一氧化碳(CO)接触是美国人类中毒的主要原因,每年有50,000例。目前的治疗方法,常压氧或高压氧,疗效有限,难以提供。目前还没有解毒剂疗法。我们对一氧化碳的毒性作用有两方面的理解:一氧化碳直接与血红蛋白结合,降低血液的携氧能力,一氧化碳直接与细胞色素c氧化酶中的血红素结合,抑制线粒体的呼吸。CO中毒的主要后遗症-心血管功能障碍和急性和长期神经功能障碍-依赖于线粒体功能受损。我们实验室已经开发出一种对一氧化碳具有非常高亲和力的试剂,重组人脑红蛋白(RNgb),它有可能减少一氧化碳中毒的毒性效应。因此,我们提出假设,用rNgb治疗可以逆转CO中毒对线粒体功能的毒性效应。为了验证这一假说,我们将首先使用类似Clark的电极进行体外研究,以进一步表征CO对分离的线粒体和心脏组织呼吸的毒性效应,并证明rNgb可以逆转CO对线粒体呼吸的毒性效应。其次,在体内CO中毒模型中,我们将显示rNgb治疗可以逆转通过功能MRI变化(分数各向异性)以及血乳酸和血糖水平评估的病理变化。这些结果将为rNgb作为一种潜在的CO中毒治疗剂提供临床前的概念证明。与此同时,通过NIH Smartt计划,我们正在进行药理学和毒理学测试,并扩大药物制造能力。NRSA奖将使我作为一名接受过肺部和重症监护培训的研究员,获得一个独特的机会,利用我的导师Mark Gladwin博士现有的研发基础设施,获得关于疾病动物模型、线粒体生物学和病理生理结果的高级培训。此外,我正在卡内基梅隆大学泰珀商学院攻读创业MBA课程,该课程将提供金融、统计建模和关键工具方面的广泛培训,以将一种潜在的治疗药物从工作台带到床边。我的导师格拉德温博士是一氧化氮和珠蛋白生物化学方面的专家,以及药物从实验室到临床的翻译开发方面的专家,我的导师格拉德温博士和我的同事导师希瓦博士是线粒体生物学专家,加上匹兹堡大学提供的大量资源,将使我能够开发新的翻译研究技能,特别是开发新的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason J Rose其他文献
Jason J Rose的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason J Rose', 18)}}的其他基金
University of Maryland BaltImore Life Science Discovery (UM-BILD) Accelerator
马里兰大学巴尔的摩生命科学发现 (UM-BILD) 加速器
- 批准号:
10783358 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning
用于治疗一氧化碳中毒的血红蛋白解毒剂
- 批准号:
10282997 - 财政年份:2020
- 资助金额:
$ 7.8万 - 项目类别:
Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning
用于治疗一氧化碳中毒的血红蛋白解毒剂
- 批准号:
10296690 - 财政年份:2020
- 资助金额:
$ 7.8万 - 项目类别:
Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning
用于治疗一氧化碳中毒的血红蛋白解毒剂
- 批准号:
9908358 - 财政年份:2020
- 资助金额:
$ 7.8万 - 项目类别:
Discovering and Developing Recombinant Molecular Scavenging Agents for the Treatment of Carbon Monoxide Induced Cardiovascular Dysfunction
发现和开发用于治疗一氧化碳引起的心血管功能障碍的重组分子清除剂
- 批准号:
10213117 - 财政年份:2018
- 资助金额:
$ 7.8万 - 项目类别:
Discovering and Developing Recombinant Molecular Scavenging Agents for the Treatment of Carbon Monoxide Induced Cardiovascular Dysfunction
发现和开发用于治疗一氧化碳引起的心血管功能障碍的重组分子清除剂
- 批准号:
10442531 - 财政年份:2018
- 资助金额:
$ 7.8万 - 项目类别:
Developing a Low-Cost Intelligent Ventilator with Remote Control for Rapid, Global Deployment and Minimal Healthcare Provider Exposure
开发具有远程控制功能的低成本智能呼吸机,以实现快速全球部署并最大限度地减少医疗保健提供者的暴露
- 批准号:
10166226 - 财政年份:2018
- 资助金额:
$ 7.8万 - 项目类别:
Discovering and Developing Recombinant Molecular Scavenging Agents for the Treatment of Carbon Monoxide Induced Cardiovascular Dysfunction
发现和开发用于治疗一氧化碳引起的心血管功能障碍的重组分子清除剂
- 批准号:
9973110 - 财政年份:2018
- 资助金额:
$ 7.8万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 7.8万 - 项目类别:
Continuing Grant